Seeking Balance
in COVID-19
Immune Storms
READ MORE »
Powering
Relentless
Science
READ MORE »
Realizing Promise
of First Dual-Acting,
Broad-Spectrum
Immunomodulator
READ MORE »
Driving First
Non-Injection
Retinal Disease
Treatment
READ MORE »

Our Mission

To restore health and save lives

Our Values

Power science
Strive relentlessly
Support each other and humankind

Read More »

Rescue, Repair, and Restore

EOM Pharmaceuticals is focused on developing and commercializing first-in-class treatments built on proprietary innovations designed to rescue, repair, and restore health.

Our lead investigational candidate EOM613 is the first-and-only dual-acting, broad-spectrum immunomodulator with a potential to address multiple therapeutic challenges, including treating the most severe effects of COVID-19, and EOM147, the first potential squalamine eye drop treatment for retinal diseases such as Age-related Macular Degeneration (AMD) that does not require intraocular injection.

Watch how EOM613 may work to re-establish natural balance in an immune system that has been confronted by an invading antigen, pathogen, or virus.

Our Pipeline

EOM613

An investigational, dual-acting, broad-spectrum immunomodulator designed to have both an anti-inflammatory effect at the site of cytokine and chemokine overactivity, and a pro-inflammatory effect, when needed. By re-establishing natural balance, EOM613 may rescue, repair, and restore an immune system that has been confronted by an invading antigen, pathogen, or virus.

EOM147

A first-in-class small molecule anti-angiogenic drug with a novel intracellular mechanism of action for the treatment of proliferative diabetic retinopathy, diabetic macular edema, branch and central retinal vein occlusions, and wet age-related macular degeneration (AMD). The novel formulation represents a potential breakthrough because it does not require intraocular injection into the eye and, if approved, would be the first topically administered eye drop to treat retinal diseases.

News Highlights

EOM PHARMACEUTICALS ANNOUNCES ITS PRE-IND MEETING REQUEST WITH U.S. FDA TO EVALUATE PLANS FOR A PHASE 2 CLINICAL TRIAL OF ITS INVESTIGATIONAL DUAL-ACTING, BROAD-SPECTRUM IMMUNOMODULATOR IN COVID-19 PATIENTS

December 24, 2020

MONTVALE, N.J. – December 23, 2020 — EOM Pharmaceuticals, Inc., a privately held, clinical-stage company, today announced it has filed a pre-Investigational New Drug Application (pre-IND) meeting request and complete pre-IND briefing documents with the U.S. Food and Drug Administration (FDA) to discuss the company’s plans to evaluate the safety and efficacy of its dual-acting, […]

READ MORE »

EOM PHARMACEUTICALS APPOINTS BUSINESS VETERAN WAYNE I. DANSON AS CHIEF FINANCIAL OFFICER AND TREASURER

December 17, 2020

MONTVALE, NEW JERSEY – December 17, 2020 — EOM Pharmaceuticals, a privately held, clinical-stage company, announced today the appointment of business veteran Wayne I. Danson, CPA, as Chief Financial Officer and Treasurer. Mr. Danson will be responsible for leading the Company’s financial operations including financial planning and analysis, capital markets, investor relations, accounting, tax and […]

READ MORE »